Funder
Janssen Research and Development
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Urology,Oncology
Reference27 articles.
1. ERLEADA (apalutamide) [prescribing information]. Janssen Pharmaceutical Companies, Horsham, PA; 2020.
2. ERLEADA (apalutamide). [Summary of Product Characteristics]. The electronic Medicines Compendium (eMC) Web site (https://www.ema.europa.eu/en/documents/product-information/erleada-epar-product-information_en.pdf) and https://www.ema.europa.eu/en/medicines/human/EPAR/erleada.
3. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79:150–8.
4. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl J Med. 2018;378:1408–18.
5. Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:1404–16.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献